How Much Does Wegovy Cost in 2026? (With and Without Insurance)

Pricing Detail

What Determines the Price

Wegovy is the higher-dose (2.4 mg) semaglutide brand manufactured by Novo Nordisk for chronic weight management. As of June 2026, its U.S. wholesale acquisition cost is approximately $1,349 per month, the highest of the four major GLP-1 brands.

What patients actually pay is shaped by four factors: (1) whether the plan covers obesity medications at all — many commercial plans still carve out anti-obesity drugs; (2) prior authorization criteria, typically BMI thresholds and documented prior weight-loss attempts; (3) eligibility for the Wegovy Savings Card or NovoCare Pharmacy self-pay program; and (4) the diagnosis on the prescription, since Medicare coverage now distinguishes between weight loss and cardiovascular-event reduction.

Coverage

Insurance Coverage Requirements

Commercial insurance: coverage varies dramatically by employer and plan. When obesity benefits are included, prior authorization typically requires BMI ≥30 (or ≥27 with a comorbidity such as hypertension, dyslipidemia, type 2 diabetes, or sleep apnea), often documentation of a prior structured weight-loss attempt, and renewal based on response (commonly ≥5% weight loss at 6 months). Approved patients usually pay a $25–$200 tiered copay.

Medicare Part D: the 2024 FDA label expansion based on the SELECT trial added a cardiovascular-event-reduction indication for adults with overweight or obesity and established cardiovascular disease. As a result, Medicare Part D plans now cover Wegovy for that specific indication; Medicare still does not cover Wegovy when prescribed solely for weight loss.

Medicaid: state-by-state variability is even larger than commercial; some states cover Wegovy for obesity, most do not. Confirm with your specific state program.

Manufacturer Programs

Manufacturer Savings Programs

Wegovy Savings Card: for commercially insured patients with an FDA-approved indication and the necessary prior authorization, the savings card can reduce out-of-pocket cost to as low as $25 per month. It does not apply to Medicare, Medicaid, TRICARE, or VA patients.

NovoCare Pharmacy self-pay: Novo Nordisk ships Wegovy directly to eligible cash-pay patients at $499/month for all doses with a valid U.S. prescription. This is meaningfully below the retail cash price and is the most accessible self-pay path for the medication.

Patient assistance: limited needs-based programs exist through the Novo Nordisk Patient Assistance Program for patients without insurance who meet income criteria. Approval is not guaranteed and the application process takes weeks.

What to Avoid

Why Compounded Semaglutide Is Cheaper — and Riskier

Compounded semaglutide marketed at $200–$400/month is the same conversation as Ozempic: not FDA-approved, documented dosing errors and adverse events, and the use of semaglutide salt forms (semaglutide sodium, semaglutide acetate) that are not the same active ingredient as Wegovy. With semaglutide off the FDA shortage list, the legal basis for routine compounding has narrowed sharply.

If brand Wegovy is unaffordable, the better-medicine path is usually a switch in strategy — a physician-supervised conversation about Zepbound (often a better-priced cash option via LillyDirect single-dose vials), a different medication class, or working harder on appeals and prior authorizations — not a compounded vial of unknown provenance.

Physician-Supervised Care

What a Physician-Supervised Program Includes — and What That Costs

The medication is only part of the bill. A real Wegovy program — the kind Haute MD physicians build — also pays for the medicine around it: baseline labs, body composition, nutrition therapy, training programming, and quarterly reassessment.

• ·New-patient consult and intake: typically $300–$750 cash, often covered as an office visit by commercial insurance.
• ·Baseline lab panel (CBC, CMP, HbA1c, lipid panel, TSH, vitamin D, hormone panel where indicated): $150–$600 cash, often covered by insurance with appropriate diagnosis codes.
• ·Body-composition assessment (DEXA or clinical-grade bioimpedance): $75–$250 per scan; quarterly is standard.
• ·Nutrition therapy with a registered dietitian: $125–$300 per visit; some plans cover medical nutrition therapy for obesity or diabetes.
• ·Follow-up visits during titration (monthly for the first 4–6 months): $150–$400 each cash, or a standard copay with insurance.
• ·Bundled concierge GLP-1 programs in major markets typically run $400–$900 per month on top of the medication, including unlimited messaging, structured nutrition and training support, and quarterly labs and DEXA.

These costs separate medical weight loss from a $200/month compounded vial. A physician-led Wegovy program is a treatment for a chronic disease — priced and structured accordingly.